Cohort study for investigating treatment reality in resectable and unresectable stage III non-small-cell lung carcinoma populations in Japan (SOLUTION study)
Not Applicable
Completed
- Conditions
- Stage III non-small cell lung cancer
- Registration Number
- JPRN-UMIN000031385
- Lead Sponsor
- AstraZeneca K.K
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 1000
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients receiving unapproved drugs for the treatment of NSCLC at the initiation of this study 2. Patients who are regarded as inappropriate to participate in the study by the primary investigators
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method [1st cohort] 1.To estimate OS in the overall cohort population [2nd cohort] 2.To estimate OS in the overall cohort population
- Secondary Outcome Measures
Name Time Method [1st cohort] 1.To estimate PFS in the overall cohort populations and OS and PFS by treatment regimen 2.To estimate ORR and TTDM in the overall cohort populations and by treatment regimen 3.To evaluate safety profile of treatment for patients with stage III NSCLC in terms of treatment-related adverse events including pneumonitis/radiation pneumonitis 4.To summarize treatment outcomes stratified by clinical characteristics [2nd cohort] 5.To summarize the patient characteristics at initial diagnosis in overall cohort population and in type of initial treatments 6.To estimate OS, PFS, and DFS (in case of surgery) in type of initial treatment 7.To estimate ORR and TTDM in type of initial treatment, without surgery 8.To evaluate safety profile of treatment for patients with stage III NSCLC in terms of treatment-related adverse events including pneumonitis/radiation pneumonitis 9.To summarize treatment outcomes stratified by clinical characteristics